Surmodics Announces FDA Clearance of a New .018 " Low-Profile PTA Balloon Dilation Catheter

Company received FDA 510(k) clearance Continued progress in R&D whole-product solutions pipeline EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its .018” Low-Profile percutaneous transluminal angioplasty (PTA) balloon dilation catheter, designed and indicated for a broad...This story is related to the following:Catheters
Source: Industrial Newsroom - Health, Medical and Dental Supplies - Category: Medical Devices Source Type: news

Related Links:

In conclusion, the up-regulation of Lin28a exerts its modulatory effect on VSMCs' proliferation and migration, which may play a critical role in contributing to pathological formation of restenosis. PMID: 32710472 [PubMed - as supplied by publisher]
Source: J Cell Mol Med - Category: Molecular Biology Authors: Tags: J Cell Mol Med Source Type: research
The current guidelines for the treatment of femoropopliteal disease recommend percutaneous transluminal angioplasty [PTA] either alone or in combination with atherectomy, drug-coated balloon angioplasty or angioplasty integrated with stent implantation as feasible alternatives. Although the use of stents has improved the patency rates following PTA in femoropopliteal disease, the rates of in-stent stenosis [ISR] ranges from 15% to 32%. The evidence and guidelines for the management of ISR post femoropopliteal stent implantation are not conclusive.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
ConclusionThis DCB-PTA cohort study showed a  relatively low intracranial complication rate of 6% with a symptomatic recurrence rate of 12%. Larger trials are needed to validate these promising observations.
Source: Clinical Neuroradiology - Category: Neurology Source Type: research
Percutaneous transluminal angioplasty (PTA) is increasingly requested in the therapy of peripheral arterial occlusive disease. The evaluation of the technical result after balloon angioplasty with regard to ba...
Source: BMC Medical Imaging - Category: Radiology Authors: Tags: Research article Source Type: research
This study compares the outcomes of atherectomy to percutaneous transluminal angioplasty (PTA) and stenting for treatment of isolated femoropopliteal disease.
Source: Annals of Vascular Surgery - Category: Surgery Authors: Tags: Clinical Research, Basic Science Source Type: research
In this study, we sought to investigate the efficacy of the percutaneous transluminal angioplasty method for the treatment of critical limb ischemia (CLI) in patients with Buerger's disease in our modest cohort. METHODS: Patients diagnosed with CLI secondary to Buerger's disease who underwent percutaneous transluminal angioplasty between May 2014 and June 2017 were retrospectively investigated. Patient demographics, presentations, procedural details, responses to percutaneous treatment, complications, limb salvage, wound healing, reinterventions, and early follow-up data were recorded. RESULTS: The cohort included ...
Source: The Journal of Invasive Cardiology - Category: Cardiology Tags: J Invasive Cardiol Source Type: research
Condition:   Peripheral Artery Disease Intervention:   Device: AcoArt Orchid (0.035 " ), AcoArt Tulip (0.018 " ) and AcoArt Litos (0.014 " ) percutaneous transluminal angioplasty (PTA) paclitaxel drug coated balloon catheter manufactured by Acotec Scientific Co., Ltd. Sponsor:   Acotec Scientific Co., Ltd Not yet recruiting
Source: - Category: Research Source Type: clinical trials
AbstractCholesterol crystal embolization (CCE) is a rare, mainly iatrogenic condition. The proportion of CCE after cardiovascular procedures has not been fully elucidated. The purpose of this study was to determine the proportion of CCE diagnosed after cardiovascular procedures and to identify risk factors for CCE occurrence. Data on patients aged older than 40  years who underwent cardiovascular procedures between July 2010 and March 2017 were extracted from the Japanese Diagnosis Procedure Combination database. Inpatients diagnosed with CCE within 1 year after procedures in the same hospital were identified. Lo...
Source: Heart and Vessels - Category: Cardiology Source Type: research
The aim was to review and analyse the literature on clinical outcomes of drug coated balloon (DCB) vs. standard percutaneous transluminal angioplasty (PTA) for the treatment of infrapopliteal arterial disease.
Source: Journal of Vascular Surgery - Category: Surgery Authors: Source Type: research
To ascertain the safety and mid-term outcomes of RotarexS rotational atherectomy plus thrombectomy device (Straub Medical AG, Wangs, Switzerland) with or without adjunctive treatment (e.g., percutaneous transluminal angioplasty, PTA/Drug-coated balloon, DCB/stenting) in patients with in-stent restenosis (ISR) or occlusion in the iliac and/or infrainguinal arteries.
Source: Journal of Vascular and Interventional Radiology : JVIR - Category: Radiology Authors: Tags: Scientific Session 34 Source Type: research
More News: Angioplasty | Baloon Angioplasty | Food and Drug Administration (FDA) | Medical Devices | Peripheral Angioplasty